The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 28, 2017
Filed:
Sep. 09, 2015
Applicant:
Magforce Ag, Berlin, DE;
Inventors:
Assignee:
MAGFORCE AG, Berlin, DE;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/50 (2006.01); A61K 9/51 (2006.01); A61K 33/00 (2006.01); A61K 41/00 (2006.01); A61K 9/00 (2006.01); A61K 9/10 (2006.01); A61K 33/24 (2006.01); A61K 33/26 (2006.01); A61K 33/30 (2006.01); A61K 33/32 (2006.01); A61K 33/34 (2006.01); A61K 45/06 (2006.01); A61N 1/40 (2006.01); B82Y 5/00 (2011.01); A61K 31/136 (2006.01); A61K 31/282 (2006.01); A61K 31/407 (2006.01); A61K 31/513 (2006.01); A61K 31/546 (2006.01);
U.S. Cl.
CPC ...
A61K 41/0052 (2013.01); A61K 9/0009 (2013.01); A61K 9/0019 (2013.01); A61K 9/10 (2013.01); A61K 9/5094 (2013.01); A61K 9/5115 (2013.01); A61K 9/5146 (2013.01); A61K 31/136 (2013.01); A61K 31/282 (2013.01); A61K 31/407 (2013.01); A61K 31/513 (2013.01); A61K 31/546 (2013.01); A61K 33/00 (2013.01); A61K 33/24 (2013.01); A61K 33/26 (2013.01); A61K 33/30 (2013.01); A61K 33/32 (2013.01); A61K 33/34 (2013.01); A61K 45/06 (2013.01); A61N 1/406 (2013.01); B82Y 5/00 (2013.01); Y10S 977/773 (2013.01);
Abstract
The present invention relates to compositions containing nanoparticies and uses of said composition for transferring therapeutically active substances into cells by means of specifically coated nanoparticles. The chemical design of the particles is such that a large amount thereof is absorbed into the cells. No direct bond between nanoparticle and the therapeutically active substance is required for the transfer into the cells. Thanks to said transfer, an increased efficacy of the substance and simultaneously reduced systemic toxicity is achieved, i.e. an increase in the efficacy while the side effects are reduced.